Randomized phase III trial of liposomal daunorubicin versus doxorubicin, bleomycin, and vincristine in AIDS-related Kaposi's sarcoma

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
P S GillM E Ross

Abstract

To compare the safety and efficacy of liposomal daunorubicin (DaunoXome; NeXstar Pharmaceuticals, Inc, Boulder, CO) with a reference regimen of doxorubicin, bleomycin, and vincristine (ABV) in advanced AIDS-related Kaposi's sarcoma (KS). In a prospective randomized phase III trial, 232 patients were randomized to receive DaunoXome 40 mg/m2 or a combination regimen of doxorubicin 10 mg/m2, bleomycin 15 U, and vincristine 1 mg, administered intravenously every 2 weeks. Treatment was continued until complete response (CR), disease progression, or unacceptable toxicity. Of 232 patients randomized, 227 were treated: 116 with DaunoXome and 111 with ABV. The overall response rate (CR or partial response [PR]) was 25% (three CRs and 26 PRs) for DaunoXome and 28% (one CR and 30 PRs) for ABV. The difference in response rates was not statistically significant. The median survival time was 369 days for DaunoXome patients and 342 days for ABV patients (P = .19). The median time to treatment failure was 115 days for DaunoXome and 99 days for ABV (P = .13). ABV patients experienced significantly more alopecia and neuropathy (P < .0001). DaunoXome patients experienced more grade 4 neutropenia (P = .021). Cardiac function remained stable, with ...Continue Reading

Citations

Aug 26, 1998·Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology : Official Publication of the International Retrovirology Association·C L BennettS Stewart
Apr 1, 1999·Pediatric Hematology and Oncology·E Mantadakis, B Kamen
Nov 24, 1999·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·P S GillD T Scadden
Feb 16, 2000·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·A TulpuleP S Gill
Mar 29, 2000·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·G NastiU Tirelli
Sep 18, 2001·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·B HolkovaA Chanan-Khan
Feb 2, 2002·American Journal of Clinical Oncology·Eric RosenthalUNKNOWN DNX Study Group
Aug 16, 2002·American Journal of Clinical Dermatology·Anna M CattelanSavina M L Aversa
Oct 16, 2004·Expert Review of Anti-infective Therapy·Yoshiyasu Aoki, Giovanna Tosato
Feb 10, 2007·Expert Review of Anticancer Therapy·Amy HansenDimitrios Lagos
May 26, 2007·The Journal of Laryngology and Otology·P A KonstantinopoulosL Pantanowitz
Jul 11, 2008·The Oncologist·S Yousuf ZafarJon P Gockerman
Jun 6, 2009·BioDrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy·Ryan J SullivanBruce J Dezube
Sep 15, 2010·Nature Reviews. Clinical Oncology·Rakesh K Jain, Triantafyllos Stylianopoulos
Apr 27, 2011·Expert Opinion on Pharmacotherapy·Cecilia SgadariBarbara Ensoli
Jan 16, 2013·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Gertjan J L KaspersUrsula Creutzig
Feb 15, 2013·Expert Review of Anticancer Therapy·Alessia Dalla PriaMark Bower
Aug 21, 2013·Orvosi hetilap·Eszter KirillyGyörgy Bagdy
Oct 19, 2016·Journal of Cardiovascular Medicine·Pier P BassareoGiuseppe Mercuro
Apr 18, 2018·Molecules : a Journal of Synthetic Chemistry and Natural Product Chemistry·Temidayo O B OlusanyaAmal Ali Elkordy
Aug 18, 2018·Cancer Chemotherapy and Pharmacology·Isabel SousaPaula Soares
Sep 25, 2019·International Journal of Molecular Sciences·Ngoc Thuy Trang LeThai Thanh Hoang Thi
Dec 10, 2019·Current Opinion in Oncology·Nicolas Dupin
Dec 11, 1999·Proceedings of the Association of American Physicians·W A Blattner
Mar 20, 2001·Current Oncology Reports·F M Muggia
Mar 17, 1999·Japanese Journal of Cancer Research : Gann·Y MatsumuraT Kakizoe
Jun 8, 2002·Breast Cancer Research : BCR·John W Park
Dec 1, 1996·AIDS Patient Care and STDs·J C Wernz
Nov 6, 2002·Japanese Journal of Cancer Research : Gann·Yoshihisa TsukiokaTadao Kakizoe
Sep 7, 2000·Journal of Clinical Pharmacology·J P DutcherP H Wiernik
Feb 9, 2002·AIDS·Steven A MilesUNKNOWN AIDS Malignancy Consortium
Oct 9, 2004·International Journal of Cancer. Journal International Du Cancer·Charles L M OlwenyHarvey Schipper
May 25, 2004·Expert Opinion on Investigational Drugs·Anna Maria CattelanSavina Maria Lucia Aversa
Oct 7, 2003·Oncogene·Massimiliano BerrettaUmberto Tirelli
Jul 20, 2005·Anti-cancer Drugs·Ralf-Dieter HofheinzAndreas Hochhaus

❮ Previous
Next ❯

Related Concepts

Related Feeds

AIDS Malignancies (ASM)

HIV infection increases the risk of non-communicable diseases common in the aged, including cardiovascular disease, neurocognitive decline, non-aids malignancies, osteoporosis, and frailty. Discover the latest research in AIDS malignancies.

HIV/AIDS-Related Malignancies

HIV/AIDS infection increases the risk of non-communicable diseases common in the aged including HIV/AIDS-related malignancies. Discover the latest research in HIV/AIDS-related malignancies.